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Abstract
Background: Melanoma inhibitory activity (MIA) is a small secreted protein that interacts with
extracellular matrix proteins. Its over-expression promotes the metastatic behavior of malignant
melanoma, thus making it a potential prognostic marker in this disease. In the present study, the
expression and functional role of MIA was analyzed in pancreatic cancer by quantitative real-time
PCR (QRT-PCR), immunohistochemistry, immunoblot analysis and ELISA. To determine the
effects of MIA on tumor cell growth and invasion, MTT cell growth assays and modified Boyden
chamber invasion assays were used.
Results: The mRNA expression of MIA was 42-fold increased in pancreatic cancers in comparison
to normal pancreatic tissues (p < 0.01). In contrast, MIA serum levels were not significantly
different between healthy donors and pancreatic cancer patients. In pancreatic tissues, MIA was
predominantly localized in malignant cells and in tubular complexes of cancer specimens, whereas
normal ductal cells, acinar cells and islets were devoid of MIA immunoreactivity. MIA significantly
promoted the invasiveness of cultured pancreatic cancer cells without influencing cell proliferation.
Conclusion: MIA is over-expressed in pancreatic cancer and has the potential of promoting the
invasiveness of pancreatic cancer cells.
Background
Despite improvements in diagnosis and treatment, pan-
creatic cancer remains one of the most common causes of
cancer-related deaths in the world [1]. One of the reasons
for the dismal prognosis is the propensity of pancreatic
cancer cells to invade surrounding tissues and to metasta-
size. Melanoma inhibitory activity (MIA) is a small
secreted protein normally expressed in cartilage and also
produced by malignant melanoma cells and to a lesser
degree by breast, colon cancer, and glioblastoma cells [2-
4]. The exact biological functions of MIA are still unclear,
but recent evidence indicates an important role of MIA in
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tumor progression and metastasis. MIA has been shown
to interact with the components of the extracellular
matrix, such as fibronectin and laminin, possibly via the
binding motif for integrins. For example, MIA inhibits the
attachment of suspended melanoma cells to surfaces
coated with laminin or fibronectin [5]. In addition, over-
expression of MIA in melanoma cells induces an aggres-
sive tumor type by enhancing the metastatic potential. It
has been shown that there is a correlation between
increased plasma levels of MIA and a more advanced met-
astatic disease state in malignant melanoma patients [6].
Previously, using DNA array technology, we have demon-
strated an increase of MIA mRNA expression in pancreatic
cancer in comparison with the normal pancreas [7]. In the
present study, we have further investigated the expression
and localization of MIA, and its functional role in pancre-
atic cancer.
Results
To quantify the mRNA expression of MIA in pancreatic tis-
sues, QRT-PCR was performed using RNA from pancreatic
cancer tissues (n = 23) and normal pancreatic tissue sam-
ples (n = 17). The analysis revealed a 42 ± 28-fold increase
(p = 0.0013) of MIA mRNA levels in pancreatic cancer tis-
sues compared to the normal pancreas (Fig. 1A). To deter-
mine the exact localization of MIA in pancreatic tissues,
immunostaining was carried out in 32 primary pancreatic
cancers and in 17 normal pancreatic tissue samples. In the
normal pancreas, MIA immunoreactivity was absent in
ductal, acinar and islets cells, but was observed in the
muscular layer of vessels (Fig. 2A–C). In contrast, in pan-
creatic cancer tissues, MIA immunoreactivity was moder-
ate in the cancer cells and in tubular complexes in CP-like
lesions adjacent to the tumor mass (Fig. 2D–F), and in
blood vessels and nerve ganglia (Fig. 2G,H). Further anal-
ysis to correlate different tumor stages and grades with
MIA immunoreactivity in pancreatic cancer tissues was
performed. No difference between tumor stages, grades
and MIA immunostaining was observed. To ensure the
specificity of the antibody used, a malignant melanoma
metastasis to the peritoneum was also analyzed. Strong
cytoplasmic MIA staining of the malignant melanoma
cells but not the surrounding tissues could be detected
(Fig. 2I). Since a correlation between increased serum lev-
els of MIA in malignant melanoma and more advanced
metastatic disease has been reported previously, we next
investigated MIA serum levels in pancreatic cancer
patients and healthy donors. The mean values of MIA
serum levels were 8.3 ± 3.56 ng/ml in pancreatic cancer
patients (n = 50) and 8.82 ± 2.01 ng/ml in control sub-
jects (n = 14) (n.s.) (Fig. 1B). Further analysis revealed
that there was also no significant difference between
patient groups with different tumor stages or grades.
To determine the functional role of MIA in pancreatic can-
cer, we first investigated MIA expression in pancreatic cell
lines. QRT-PCR analysis revealed relatively high MIA
mRNA levels in Mia PaCa-2, Panc-1, and SU8686 pancre-
atic cancer cells compared to the other cell lines (Fig. 3A).
Immunoblot analysis was employed to evaluate MIA pro-
tein levels in pancreatic cancer cell lines. This analysis
revealed a band of 15 kDa corresponding to the known
size of MIA in the control melanoma cell line B16 (B78/
H1), whereas it was only weakly present in Mia Paca-2,
MIA mRNA expression and serum levels Figure 1
MIA mRNA expression and serum levels. A: MIA 
mRNA values in normal pancreatic tissues and pancreatic 
ductal adenocarcinoma (cancer) tissues by real-time quantita-
tive polymerase chain reaction, as described in the Methods 
section. Values were normalized to housekeeping genes 
(cyclophilin B and hypoxanthine guanine phosphoribosyl-
transferase). B: ELISA was carried out as described in the 
Methods section. Fifty pancreatic cancer sera samples and 14 
healthy donor sera samples were analyzed. The horizontal 
lines represent the mean expression levels.Cancer Cell International 2005, 5:3 http://www.cancerci.com/content/5/1/3
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Panc-1, and SU8686 pancreatic cancer cell lines, and
below the level of detection in the other tested cell lines
(Fig 3B). To confirm the specificity of the signal, immuno-
precipitation was performed. This demonstrated an
immunospecific band at 15 kDa in B78/H1, Mia PaCa-2,
and SU8686 cell lines (Fig. 3C).
In order to determine the effects of MIA on the prolifera-
tion of pancreatic cancer cells, MTT cell growth assays
were performed next. This analysis revealed no significant
effects of MIA on the proliferation of pancreatic cancer
cells (data not shown). To analyze whether MIA may pro-
mote invasiveness of pancreatic cancer cells, Matrigel-
based invasion assays using a modified Boyden chamber
were carried out in T3M4 and Aspc-1 pancreatic cancer
cell lines that exhibited relatively low MIA expression lev-
els according to QRT-PCR and Western blot data. Added
to the top chamber as described in Methods section, MIA
significantly increased the invasion of Aspc-1 by 2.4-fold
(p < 0.001) and the invasion of T3M4 by 3.1-fold (p <
0.0001) (Fig. 3D). To investigate possible mechanisms of
MIA overexpression in pancreatic cancer cells, we
Localization of MIA in pancreatic tissues Figure 2
Localization of MIA in pancreatic tissues. MIA localization in pancreatic tissues: immunohistochemistry using a MIA spe-
cific antibody was carried out as described in the Methods section. A-C: normal pancreatic tissues; D-H: pancreatic cancers; I: 
malignant melanoma metastasis to the peritoneum. Note that in melanoma metastasis the signal is red (using HistoMark Red 
phosphatase system) to differentiate the staining from the brown pigment in melanoma cells.
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Expression and effects of MIA in cultured pancreatic cancer cells Figure 3
Expression and effects of MIA in cultured pancreatic cancer cells. A: MIA mRNA levels in indicated pancreatic cancer 
cell lines were determined by real-time quantitative polymerase chain reaction, as described in the Methods section. Data are 
presented as median + SD of MIA mRNA copies per µl of input cDNA normalized to housekeeping genes CPB and HPRT. B: 
30 µg protein lysates of the indicated cell lines were subjected to immunoblotting analysis using a specific MIA antibody, as 
described in the Methods section. C: Immunoprecipitation analysis was carried out as described in the Methods section. D: An 
in vitro cell invasion assay was performed using 8 µM filters coated with Matrigel, as described in the Methods section. 4 × 
105of the indicated pancreatic cancer cells were seeded onto the filters in 10% serum overnight, and then treated as indicated 
for 24 h. Invaded cells were stained and counted. The values shown are the mean ± SEM obtained from three independent 
experiments.
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analyzed whether micro-environmental changes may
modulate MIA expression. Neither TGF-β1 nor hypoxia
was able to alter MIA mRNA expression, according to the
QRT-PCR analysis of correspondingly treated pancreatic
cancer cell lines (data not shown).
Discussion
One of the most devastating aspects of malignant growth
is the emergence of cancer foci in organs distant from the
primary tumor, with most cancer mortality being related
to metastases. Thus, understanding the molecular mecha-
nisms underlying the metastatic process is one of the most
important issues in cancer research.
Pancreatic cancer is characterized by aggressive local
tumor growth and early systemic tumor spread [8-10].
Many factors are involved in transforming pancreatic can-
cer into a highly aggressive and metastatic disease, such as
alterations in cell-cell interaction [11], deregulated expres-
sion of extracellular proteases [12], and metastasis-associ-
ated genes such as KAI-1, heparanase [13,14] and a
number of other molecules.
Another important aspect of the metastasis process is neo-
angiogenesis. Angiogenesis itself encompasses a cascade
of sequential processes emanating from microvascular
endothelial cells, which are stimulated to proliferate,
degrade the endothelial basement membranes of parental
vessels, migrate, penetrate host stroma, and initiate a cap-
illary sprout [15]. Numerous angiogenic factors are over-
expressed in pancreatic cancer, including vascular
endothelial growth factor (VEGF), bFGF, and angiogenin,
as well as members of the TGF-β, and FGF gene families
[16-20]. In order to migrate and metastasize, cancer cells
have to overcome and move through natural barriers cre-
ated by cell-cell and cell-extracellular matrix (ECM) adhe-
sion structures. Any destruction in cell-cell and ECM
networks will facilitate motility and allow the cancer cells
to migrate and metastasize. The invasion and metastatic
potential of cancer cells depends on their intrinsic proper-
ties and the host microenvironment [21].
Melanoma inhibitory activity (MIA) increases cell motil-
ity by decreasing the attachment of the cells to the extra-
cellular matrix (ECM). Overexpression of MIA leads to
increased metastasis of malignant melanoma cells by
enhancing invasion and extravasation [22,23]. In the
present study we show by QRT-PCR and immunohisto-
chemistry that MIA is significantly over-expressed in pan-
creatic cancer in comparison with normal pancreatic
tissues. These data are in agreement with findings in
malignant melanoma and breast cancer, in which MIA is
also highly expressed [6,24,25].
In contrast to observations in malignant melanoma,
where MIA has been established as a reliable marker for
prognosis [6,24], we could not detect either a significant
difference of MIA serum levels between pancreatic cancer
patients and donors or a significant difference between
patients at different stages of pancreatic cancer. Therefore,
MIA cannot serve as a diagnostic or prognostic marker in
pancreatic cancer.
The reason why high MIA mRNA levels lead to high serum
levels in malignant melanoma, but not in pancreatic can-
cer, is currently not known. As to the possible role of MIA
in pancreatic cancer pathogenesis, MIA had no effect on
the proliferation of pancreatic cancer cells, similar to pre-
vious experiments employing fibroblasts, keratinocytes,
endothelial cells and lymphocytes. The only cellular sys-
tem in which MIA has been found to influence cell growth
is melanoma cells; in these cells, MIA exerts anti-prolifer-
ative effects [26].
Although MIA did not affect the growth of pancreatic can-
cer cells in vitro, its impact on the invasion was striking.
Interestingly, promotion of invasiveness of pancreatic
cancer contrasts the previously demonstrated decrease in
the invasion of MIA-treated malignant melanoma cells
[26]. A possible explanation for this dissimilarity might be
that MIA has no effect in detachment of pancreatic cancer
cells from the ECM, like in malignant melanoma [26].
Alternatively, the status of MIA-interacting partners or
downstream targets in the MIA signaling pathway may
differ between pancreatic and melanoma cancer cells. So
far, a possible correlation between MIA and other proteins
known to be involved in pancreatic cancer metastasis –
such as extracellular proteases, MMP, VEGF and bFGF –
has not been studied. Therefore, the mechanism responsi-
ble for the invasion-promoting action of MIA requires fur-
ther evaluation.
Conclusion
In conclusion, our study shows a striking overexpression
of MIA in cancerous pancreatic tissues without conse-
quent elevation of MIA in the circulation. Involvement of
MIA in regulation of invasiveness of pancreatic cancer
cells indicates that this protein may serve as a novel ther-
apeutic target in the search for anti-metastatic drugs.
Methods
Patients and tissues
Pancreatic cancer tissue samples were collected from 55
patients who underwent pancreatic cancer resection in the
Department of General Surgery at the University of Hei-
delberg, Germany, and in the Department of Visceral and
Transplantation Surgery at the University of Bern, Switzer-
land. Twelve cases were stage I, 13 cases stage II, 23 cases
stage III, and 7 cases stage IV pancreatic adenocarcinomas,Cancer Cell International 2005, 5:3 http://www.cancerci.com/content/5/1/3
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according to the Union International Contre Le Cancer
(UICC) system. According to routine pathological grad-
ing, 16 cases were well-differentiated, 22 moderately dif-
ferentiated, and 17 poorly differentiated. Normal
pancreatic tissues were collected from 34 healthy organ
donors. Pancreatic tissues were either frozen in liquid
nitrogen and stored at -80°C (for RNA and protein extrac-
tion) or immediately fixed in 4% paraformaldehyde solu-
tion and subsequently embedded in paraffin. In order to
determine MIA serum concentrations, sera from 50 pan-
creatic cancer patients (35 male, 15 female; median age 59
years; range 29–80 years) and healthy volunteers (14
male; median age 27 years; range 25–35 years) were col-
lected at the Department of General Surgery, University of
Heidelberg, Germany. Written informed consent was
obtained from all patients. The study was approved by the
Ethics Committees of the Universities of Bern, Switzer-
land, and Heidelberg, Germany.
Cell lines and culture conditions
Mia PaCa-2, T3M4, Aspc-1, Bxpc-3, Capan-1, Colo-357,
SU8686 and Panc-1 pancreatic cancer cells and B16
(cloneB78/H1) mouse melanoma cells were grown in
RPMI 1640 medium containing 10% FBS (fetal bovine
serum), 100 U/ml penicillin and 100 µg/ml streptomycin
(Invitrogen, Karlsruhe, Germany). Cells were maintained
in a 37°C humidified atmosphere saturated with 5% CO2.
For TGF-β1 induction experiments, pancreatic cancer cells
were seeded in 10 cm dishes in 10% FBS growth medium
and allowed to attach for 12 hrs. Growth medium was
replaced by serum-reduced medium (0.5% FBS), supple-
mented with 200 pM TGF-β1 for the indicated time peri-
ods. For experimental hypoxia, cells were subjected to a
hypoxic microenvironment by one hour-long flushing in
a special incubator chamber with an anoxic gas mixture
(89.25% N2, 10% CO2, 0.75%O2) and sealing of the unit.
Real-time quantitative polymerase chain reaction (QRT-
PCR)
All reagents and equipment for mRNA/cDNA preparation
were purchased from Roche Applied Science (Mannheim,
Germany). mRNA was prepared by automated isolation
using MagNA Pure LC instrument and isolation kits I (for
cells) and II (for tissue). cDNA was prepared using a 1st
strand cDNA synthesis kit for RT-PCR according to the
manufacturer's instructions. Real-time PCR was per-
formed with the Light Cycler Fast Start DNA SYBR Green
kit [27]. The number of specific transcripts was normal-
ized to housekeeping genes (cyclophilin B and hypoxan-
thine guanine phosphoribosyltransferase, HPRT). All
primers were obtained from Search-LC (Heidelberg,
Germany).
Immunohistochemistry
Briefly, consecutive paraffin-embedded tissue sections (5
µm thick) were deparaffinized and rehydrated. Antigen
retrieval was performed by pretreatment of the slides in
citrate buffer (pH 6.0) in a microwave oven for 10 min.
Thereafter, slides were cooled to room temperature in
deionized water for 5 min. After blocking of endogenous
peroxidase activity with 0.3% hydrogen peroxide and
washing in deionized water 3 times for 10 min, the sec-
tions were blocked for 1 h at room temperature with nor-
mal rabbit serum (DAKO, Hamburg, Germany), then
incubated with primary goat polyclonal anti-MIA anti-
body (A-20, Santa Cruz Biotechnology, Santa Cruz, CA;
dilution 1:35 in normal rabbit serum) overnight at 4°C.
The slides were rinsed with washing buffer (Tris-buffered
saline with 0.1% BSA) and incubated with secondary rab-
bit anti-goat HRPO-labeled IgG (Sigma-Aldrich,
Taufkirchen, Germany), diluted 1:200 for 45 min at room
temperature. After color reaction, tissues were counter-
stained with Mayer's hematoxylin. For negative control,
appropriately diluted goat IgG was used instead of the pri-
mary antibody.
Enzyme-linked immunosorbent assay (ELISA)
The amount of secreted MIA protein in cell culture super-
natants and serum samples was determined using a one-
step MIA ELISA (Roche Diagnostic GmbH, Mannheim,
Germany) according to the manufacturer's instructions.
Immunoblot
Cells were washed with ice-cold PBS and collected in lysis
buffer (50 mM Tris-HCl, 100 mM NaCl, 2 mM EDTA, 1%
SDS) containing the Complete mini-EDTA-free protease
inhibitor cocktail tablets from Roche (Roche Applied Sci-
ence, Mannheim, Germany). Lysates were centrifuged at
13,000 rpm at 4°C for 30 min, the supernatants were col-
lected, and protein concentrations were measured with
the BCA protein assay (Pierce Chemical Co., Rockford, IL,
USA) using BSA as protein standard. 20 µg of protein were
mixed with loading buffer, heated at 95°C for 5 min, sep-
arated on 12% SDS polyacrylamide gels, and transferred
onto nitrocellulose membrane at 100 V for 90 min. Mem-
branes were blocked in 5% non-fat milk in TBS-T (20 mM
Tris-HCl, 150 mM NaCl, 0.1% Tween-20) for 1 h, incu-
bated overnight at 4°C with anti-MIA antibody (A-20,
Santa Cruz) and exposed to secondary HRPO-labeled
donkey anti-goat antibody (Santa Cruz) for 1 h at room
temperature. The signal detection was performed using
the ECL system (Amersham Life Science, Amersham, UK).
Immunoprecipitation
For immunoprecipitation, pancreatic cell lines (Mia
PaCa-2 and SU8686) were suspended in lysis buffer (50
mM Tris, 150 mM NaCl, 1% Triton X-100, 25 mM NaF,
10% glycerol, 1 mM PMSF) supplemented with theCancer Cell International 2005, 5:3 http://www.cancerci.com/content/5/1/3
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Complete-TM mixture of proteinase inhibitors (Roche
Diagnostic, Mannheim, Germany) and incubated for 30
min on ice. After centrifugation, the supernatant was
transferred into a fresh vial, pre-cleared with protein A-
Sepharose beads (Santa Cruz) and incubated with 50 µl
anti-MIA antibody (A-20, Santa Cruz) overnight at 4°C.
Following addition of 30 µl of protein A-Sepharose for 1
h at 4°C, the mixture was pelleted, washed three times
with lysis buffer, and resuspended in Laemmli sample
buffer.
MTT cell growth assays
Cell growth experiments were performed using the 3-(4,
5-methylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT) assay. Pancreatic cancer cells were seeded at a den-
sity of 5000 cells/well in 96-well plates, grown overnight,
and then exposed to different concentrations of recom-
binant MIA protein as indicated. After 24 h, MTT was
added (50 µg/well) for 4 hours. Formazan products were
solubilized with acidic isopropanol, and the optical den-
sity was measured at 570 nm.
Invasion assays
Invasion assays were performed in a BD Biocoat Matrigel
Invasion Chamber with 8-µm pore size (BD Biosciences,
Heidelberg, Germany) according to the manufacturer's
instructions. The Matrigel was rehydrated with 500 µl
DMEM (serum-free) and incubated in a 37°C, 5% CO2
atmosphere for 2 h. 5 × 104 cells were incubated for 24 h
and subsequently treated with MIA (100 ng/ml) [26],
which was added to the top chamber and incubated for 24
h. The non-invading cells were removed from the upper
surface of the membrane with cotton-tipped swabs. Cells
adhering to the lower surface were fixed with 75% metha-
nol mixed with 25% acetone and stained with 1% toluid-
ine blue (Sigma-Aldrich, Taufkirchen, Germany). The
whole membrane was scanned using the software of the
Zeiss KS300 and Zeiss AxioCam HR system (Jena, Ger-
many). To calculate the total number of all invading cells,
the cells were counted in every cut-out of the mosaic
image of the whole membrane using the same software.
The assays were performed in duplicate and repeated three
times.
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